These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

915 related items for PubMed ID: 30707758

  • 21. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
    Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE.
    JAMA Oncol; 2021 Jan 01; 7(1):42-50. PubMed ID: 33180106
    [Abstract] [Full Text] [Related]

  • 22. BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors.
    Song HY, Noh H, Choi SY, Lee SE, Kim SH, Kee KM, Yoo HL, Lee MY, Kang KH, Suh JH, Yang SY, Jang EJ, Lee JI, Kim DW.
    Cancer Med; 2018 Oct 01; 7(10):5107-5117. PubMed ID: 30171671
    [Abstract] [Full Text] [Related]

  • 23. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
    Bernardi S, Malagola M, Zanaglio C, Polverelli N, Dereli Eke E, D'Adda M, Farina M, Bucelli C, Scaffidi L, Toffoletti E, Deambrogi C, Stagno F, Bergamaschi M, Franceschini L, Abruzzese E, Divona MD, Gobbi M, Di Raimondo F, Gaidano G, Tiribelli M, Bonifacio M, Cattaneo C, Iurlo A, Russo D.
    Cancer Med; 2019 May 01; 8(5):2041-2055. PubMed ID: 30950237
    [Abstract] [Full Text] [Related]

  • 24. Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia.
    Molica M, Abruzzese E, Breccia M.
    Mediterr J Hematol Infect Dis; 2020 May 01; 12(1):e2020062. PubMed ID: 32952973
    [Abstract] [Full Text] [Related]

  • 25. The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort.
    Saugues S, Lambert C, Daguenet E, Roth-Guepin G, Huguet F, Cony-Makhoul P, Ansah HJ, Escoffre-Barbe M, Turhan A, Rousselot P, Tchirkov A, Hamroun D, Hermet E, Pereira B, Berger MG.
    Haematologica; 2024 Sep 01; 109(9):2893-2907. PubMed ID: 38695126
    [Abstract] [Full Text] [Related]

  • 26. Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants.
    Auewarakul CU, Huang S, Yimyam M, Boonmoh S.
    Acta Haematol; 2006 Sep 01; 116(2):114-9. PubMed ID: 16914906
    [Abstract] [Full Text] [Related]

  • 27. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
    Zhao HF, Yang YF, Liu BC, Li WM, Xu N, Liu XL, Jiang Q, Dang HB, Liang LX, Zhang Y, Song YP.
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug 14; 43(8):636-643. PubMed ID: 36709147
    [Abstract] [Full Text] [Related]

  • 28. High Level of CD8+PD-1+ Cells in Patients with Chronic Myeloid Leukemia Who Experienced Loss of MMR after Imatinib Discontinuation.
    Kwaśnik P, Zaleska J, Link-Lenczowska D, Zawada M, Wysogląd H, Ochrem B, Bober G, Wasilewska E, Hus I, Szarejko M, Prejzner W, Grzybowska-Izydorczyk O, Klonowska-Szymczyk A, Mędraś E, Kiełbus M, Sacha T, Giannopoulos K.
    Cells; 2024 Apr 22; 13(8):. PubMed ID: 38667336
    [Abstract] [Full Text] [Related]

  • 29. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
    Cortes J, Rea D, Lipton JH.
    Am J Hematol; 2019 Mar 22; 94(3):346-357. PubMed ID: 30394563
    [Abstract] [Full Text] [Related]

  • 30. e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response.
    Marcé S, Méndez A, Xicoy B, Estrada N, Cabezón M, Sturla AL, García MR, Angona A, Amat P, Escribano Serrat S, Scalzulli E, Morgades M, Senín A, Hernández-Boluda JC, Ferrer-Marín F, Anguita E, Cortés M, Plensa E, Breccia M, García-Gutierrez V, Zamora L, Grupo Español de Leucemia Mieloide Crónica (GELMC).
    J Clin Med; 2024 Jan 29; 13(3):. PubMed ID: 38337473
    [Abstract] [Full Text] [Related]

  • 31. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX.
    J Clin Oncol; 2014 Feb 10; 32(5):424-30. PubMed ID: 24323036
    [Abstract] [Full Text] [Related]

  • 32. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.
    Qin YZ, Jiang Q, Jiang H, Lai YY, Shi HX, Chen WM, Yu L, Huang XJ.
    Br J Haematol; 2018 Sep 10; 182(5):693-700. PubMed ID: 29974949
    [Abstract] [Full Text] [Related]

  • 33. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
    Pavlovsky C, Giere I, Moiraghi B, Pavlovsky MA, Aranguren PN, García J, Fernandez I, Bengió R, Milone J, Labanca V, Uriarte R, Lombardi V, Reinoso FG, Magariños AE, Martinez L, Murro H, Lastiri F, Pavlovsky S.
    Clin Lymphoma Myeloma Leuk; 2011 Jun 10; 11(3):280-5. PubMed ID: 21658656
    [Abstract] [Full Text] [Related]

  • 34. B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2 BCR-ABL Transcripts: A Case Report.
    Stella S, Massimino M, Tirrò E, Vitale SR, Scalise L, Leotta S, Pennisi MS, Puma A, Romano C, Stagno F, Sapienza G, Milone G, Manzella L.
    Anticancer Res; 2019 Jan 10; 39(1):431-435. PubMed ID: 30591491
    [Abstract] [Full Text] [Related]

  • 35. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
    Casado LF, García-Gutiérrez JV, Massagué I, Giraldo P, Pérez-Encinas M, de Paz R, Martínez-López J, Bautista G, Osorio S, Requena MJ, Palomera L, Peñarrubia MJ, Calle C, Hernández-Rivas JÁ, Burgaleta C, Maestro B, García-Ormeña N, Steegmann JL.
    Cancer Med; 2015 Jul 10; 4(7):995-1002. PubMed ID: 25756742
    [Abstract] [Full Text] [Related]

  • 36. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M, Yoshida C, Takezako N, Ohwada A, Kumagai T, Nishiwaki K, Horikoshi A, Fukuda T, Takano H, Kouzai Y, Tanaka J, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.
    Int J Clin Oncol; 2017 Oct 10; 22(5):972-979. PubMed ID: 28550414
    [Abstract] [Full Text] [Related]

  • 37. Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.
    Kockerols C, Valk PJM, Janssen JJWM, Hogenbirk P, Cornelissen JJ, Saussele S, Spiess B, Perusini MA, Kim D, Westerweel PE.
    Eur J Haematol; 2024 Nov 10; 113(5):606-613. PubMed ID: 38994654
    [Abstract] [Full Text] [Related]

  • 38. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
    Iino M, Yamamoto T, Sakamoto Y.
    Hematology; 2019 Dec 10; 24(1):355-361. PubMed ID: 30880635
    [Abstract] [Full Text] [Related]

  • 39. Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
    Saugues S, Lambert C, Daguenet E, Ansah HJ, Turhan A, Huguet F, Guerci-Bresler A, Tchirkov A, Hamroun D, Hermet E, Pereira B, Berger MG.
    Ann Hematol; 2022 Oct 10; 101(10):2241-2255. PubMed ID: 36040480
    [Abstract] [Full Text] [Related]

  • 40. Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia.
    Elsayed AG, Srivastava R, Jamil MO.
    Curr Oncol Rep; 2017 Oct 07; 19(12):77. PubMed ID: 28988389
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 46.